Glaxo SmithKline OTC Switch Potential Seen As Merger Catalyst
This article was originally published in The Tan Sheet
Executive Summary
The Rx influenza treatment Relenza tops the list of potential OTC switch candidates in the Glaxo SmithKline portfolio, according to merger details announced the week of Jan. 17.